Browse by author
Lookup NU author(s): Professor Ian HicksonORCiD
This is the authors' accepted manuscript of an article that has been published in its final definitive form by American Chemical Society, 2021.
For re-use rights please refer to the publisher's terms and conditions.
Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound 4 (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with 4. Subsequent lead optimization of 4 led to amelioration of this pathway and nomination of 5 (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC).
Author(s): Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G
Publication type: Article
Publication status: Published
Journal: Journal of Medicinal Chemistry
Year: 2021
Volume: 64
Issue: 2
Pages: 909-924
Print publication date: 28/01/2021
Online publication date: 20/01/2021
Acceptance date: 07/09/2020
Date deposited: 26/03/2021
ISSN (print): 0022-2623
ISSN (electronic): 1520-4804
Publisher: American Chemical Society
URL: https://doi.org/10.1021/acs.jmedchem.0c01563
DOI: 10.1021/acs.jmedchem.0c01563
Altmetrics provided by Altmetric
